Últimas noticias sobre Owens & Minor (NYSE:OMI) Bolsa

Owens & Minor

Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

DELL

GTLS

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: GLP, OMI, HPQ, DELL y GLTS.

5 acciones en el foco este viernes: GLP, OMI, HPQ, DELL y GLTS

Owens & Minor Inc

Singular Genomic Systems Inc COM NEW

Omid Holdings Inc

OMINECA MINING & MTLS ORD by Omineca Mining & Metals Ltd.

Omineca Mining and Metals Ltd

OmiseGO - United States Dollar

Citigroup analyst Daniel Grosslight maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Buy and lowers the price target from $13 to $11.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Owens & Minor, Lowers Price Target to $11

The Offering is expected to close on April 4, 2025, subject to customary closing conditions. The Notes will bear interest at the rate of 10.000% per year.&nbsp;
The Notes will mature on April 15, 2030 (subject to certain earlier maturity triggers). The Notes were offered at a price of 100% of their principal amount.

Offerings

Owens & Minor Reports Upsize And Pricing Of $1B Senior Secured Notes Offering

Owens & Minor Launches Private Offering Of $600M Of Senior Secured Notes Due 2030

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday.
Shares of Hello Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) fell sharply during pre-market trading after reporting weak quarterly results.
Hello Group posted fourth-quarter adjusted EPADS of 18 cents missing estimates of 21 cents per shares. The company's sales came in at $361.20 million missing expectations of $365.05 million.
Hello Group shares dipped 12.4% to $6.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Lazard, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) dipped 13% to $40.00 in pre-market trading after the company reported February assets under management.</li>
<li>loanDepot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) shares fell 10.4% to $1.44 in pre-market trading after the company reported worse-than-expected fourth-quarter revenue results and a year-over-year decrease in adjusted EPS results.</li>
<li>Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) fell 9.9% to $3.36 in today's pre-market trading after gaining 7% on Tuesday.</li>
<li>Mineralys Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) fell 8.3% to $13.10 in pre-market trading. Mineralys Therapeutics priced its $175 million public offering of 12,962,962 common shares at $13.50/share.</li>
<li>MaxCyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) slipped 7.2% to $3.22 in pre-market trading following quarterly earnings.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) fell 6.2% to $24.72 in pre-market trading. XPeng shares jumped around 15% on Tuesday after the company announced to spend up to $13.8 billion on humanoid robots.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares dipped 3.1% to $9.25 in pre-market trading. Owens &amp; Minor recently reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44245496/top-3-health-care-stocks-that-may-keep-you-up-at-night-in-q1">Top 3 Health Care Stocks That May Keep You Up At Night In Q1</a></li>
</ul>

Movers

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

MLYS

MOMO

MXCT

XPEV

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $11.6, a high estimate of $14.00, and a low estimate of $10.00. Experiencing a 25.64% decline, the current average is now lower than the previous average price target of $15.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1741644335_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Owens &amp; Minor among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Minchak</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Owens &amp; Minor. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Owens &amp; Minor compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Owens &amp; Minor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Owens &amp; Minor's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OMI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Owens &amp; Minor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Owens &amp; Minor's Background</h2>
Owens &amp; Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products &amp; Healthcare Services and Patient Direct. The Products &amp; Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products &amp; Healthcare Services segment.
<h3>Owens &amp; Minor: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Owens &amp; Minor's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 1.5%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -10.98%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Owens &amp; Minor's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -41.13%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Owens &amp; Minor's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.08%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Owens &amp; Minor's debt-to-equity ratio is below the industry average. With a ratio of 3.79, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Owens & Minor: Insights From 5 Analyst Reviews

JP Morgan analyst Michael Minchak maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Underweight and lowers the price target from $14 to $10.

JP Morgan Maintains Underweight on Owens & Minor, Lowers Price Target to $10

Baird analyst Eric Coldwell maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Neutral and raises the price target from $10 to $11.

Baird Maintains Neutral on Owens & Minor, Raises Price Target to $11

On Monday,&nbsp;Owens &amp; Minor Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) reported adjusted EPS of $0.45 for the fourth quarter of 2024, down from $0.69 a year ago but beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.52</a>.
The company reported sales of $2.70 billion, up 1.5% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44038030/owens-minor-reports-fourth-quarter-full-year-financial-results-and-announces-sale-process-underway" rel="noreferrer noopener">consensus of $2.69 billion</a>.
Patient Direct revenue of $695.02 million, up 4.6% year-over-year.
Products &amp; Healthcare Services revenue of $2 billion increased marginally by 0.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43432128/owens-minor-stock-dips-on-mixed-q4-preliminary-results-310-million-apria-goodwill-charge-details" rel="noreferrer noopener">Owens &amp; Minor Stock Dips On Mixed Q4 Preliminary Results &amp; $310 Million Apria Goodwill Charge: Details</a>
The company reported fourth-quarter adjusted operating income of $95.4 million, down from $110.8 million. Adjusted EBITDA fell from $169.6 million to $138.21 million.
The company says Citi is serving as Owens &amp; Minor&#8217;s exclusive financial advisor regarding the potential sale of the Products &amp; Healthcare Services segment.
Owens &amp; Minor CEO Edward Pesicka said the company continues to leverage its footprint and broad product offering to support home-based care for millions of patients with chronic conditions. 
&#8220;These capabilities, combined with positive demographic trends and expanding home treatment options, leaves us very bullish on the future of this business,&#8221; Pesicka said. 
Owens &amp; Minor also repaid $647 million of debt over the last two years which helped with the company&#8217;s acquisition of Rotech, he added.
Pesicka added, "Our commitment to directing capital toward the higher growth and higher margin Patient Direct segment has been increasingly evident in recent years and is consistent with our strategy. As a logical next step, we have been actively engaged in robust discussions regarding the potential sale of our Products &amp; Healthcare Services segment."
Share Buyback: The Owens &amp; Minor Board of Directors authorized a share repurchase program of up to $100 million over the next 24 months.
Guidance:&nbsp;Owens &amp; Minor expects 2025 Revenues of $10.85 billion-$11.15 billion and adjusted EPS of $1.60-$1.85 versus consensus of $10.97 billion and $1.79, respectively.
The healthcare logistics&nbsp;company expects adjusted EBITDA for 2025 to be $560 million to $590 million.
Price Action:&nbsp;OMI stock is up 9.29% at $7.53 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/44012867/sensodyne-toothpaste-maker-haleon-expects-profit-to-be-weighted-towards-second-half-of-2025" target="_blank" rel="noreferrer noopener">Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025</a></li>
</ul>

Large Cap

Guidance

Health Care

General

Healthcare Logistics Firm Owens & Minor Reports Better-Than-Expected Q4 Earnings, Plans To Repurchase $100 Million In Shares

WIIM

Owens & Minor shares are trading higher after the company reported better-than-expected Q4 financial results.

Owens & Minor Says Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services Segment

2025 Financial Outlook
The Company issued its outlook for 2025; summarized below:
<ul>
<li>Revenue for 2025 to be in a range of $10.85 billion to $11.15 billion</li>
<li>Adjusted EBITDA for 2025 to be in a range of $560 million to $590 million</li>
<li>Adjusted EPS for 2025 to be in a range of $1.60 to $1.85</li>
</ul>
The Company's outlook for 2025 excludes any impact of the previously announced Rotech acquisition, any potential transaction involving the Products &amp; Healthcare Services segment, or share repurchase activity, and contains assumptions, including current expectations regarding the impact of general economic conditions.
Key assumptions supporting the Company's 2025 financial guidance include:
<ul>
<li>Gross margin of 20.75% to 21.25%</li>
<li>Interest expense of $138 million to $142 million</li>
<li>Adjusted effective tax rate of 29.0% to 30.0%</li>
<li>Diluted weighted average shares of ~80 million</li>
<li>Capital expenditures, gross, of $250 million to $270 million</li>
<li>Stable commodity prices</li>
<li>FX rates as of 12/31/2024</li>
</ul>

Owens & Minor Expects 2025 Revenues Of $10.85B-$11.15B And Adjusted EPS Of $1.60-$1.85 Versus Consensus Of $10.97B And $1.79, Respectively

Buybacks

Owens & Minor Authorizes Share Repurchase Program of Up to $100M

Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.52 by 5.77 percent. This is a 20.29 percent decrease over earnings of $0.69 per share from the same period last year. The company reported quarterly sales of $2.70 billion which beat the analyst consensus estimate of $2.69 billion by 0.39 percent. This is a 1.50 percent increase over sales of $2.66 billion the same period last year.

Owens & Minor Q4 2024 Adj EPS $0.55 Beats $0.52 Estimate, Sales $2.70B Beat $2.69B Estimate

U.S. stock futures rose on Friday following Thursday&#8217;s sell-off. Futures of all benchmark indices advanced in premarket trading, except the small-cap gauge Russell 2000.
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell over 8% on Thursday, dragging the tech-heavy Nasdaq 100 down despite the strong quarter as its gross margins fell sequentially, caused by the ramp-up in the production of its Blackwell chips.
Meanwhile, President Donald Trump escalated tariff threats against Mexico and Canada, saying that it will go into effect as scheduled on March 4, in a social media post. He further threatened additional tariffs on China, following his pledge to impose 25% tariffs on the EU.
Investors await Friday&#8217;s personal consumption expenditure inflation data amid uncertainty over interest rate cuts as it is the Federal Reserve&#8217;s preferred inflation gauge.
The 10-year Treasury yield stood at 4.25%, while the two-year yield was at 4.05%. According <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> the CME Group's FedWatch tool, there is a 94.5% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.27%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.30%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.27%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.06%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Friday. SPY was up 0.35% to $587.09, and QQQ advanced 0.28% to $501.67, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Most sectors in the S&amp;P 500 ended lower Thursday, with technology and communication services leading the decline. However, financial and energy stocks bucked the trend.
The Nasdaq Composite dropped over 500 points, dragged down by Nvidia&#8217;s 8% plunge after its Q4 earnings.
Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) declined after missing revenue estimates, whereas, SoundHound AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) rose in after-hours after beating analyst expectations. Rocket Lab USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares dropped after a weak first-quarter guidance.
Economic data showed a slight upward revision to fourth quarter GDP according to its second reading released on Thursday. Also, initial jobless claims rose by 22,000 from the previous week to 242,000, the most in over two months and above market expectations of 221,000.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.78%</td>
<td>18,544.42</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.59%</td>
<td>5,861.57</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.45%</td>
<td>43,239.50 </td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.59%</td>
<td>2,139.66</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Ryan Detrick, the chief market strategist at Carson Research highlighted that the first quarter of a post-election year tends to be &#8220;quite weak&#8221;. &#8220;This choppy start to 2025 isn&#8217;t abnormal. Don&#8217;t panic,&#8221; he added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">As we&#39;ve noted many times, the first quarter of a post-election year tends to be quite weak. This choppy start to 2025 isn&#39;t abnormal. Don&#39;t panic. <a href="https://t.co/5tQjYeqd6G">pic.twitter.com/5tQjYeqd6G</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1895314476557312425?ref_src=twsrc%5Etfw">February 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He also continued reiterating his February seasonality stance via his X posts. He highlighted that junk corporate bonds, also called high-yield bonds, were up the past five days as the S&amp;P 500 was down over 4%.
&#8220;If the end was near like they keep telling us this wouldn&#8217;t be the case. Remain calm, this is simply seasonal late February shenanigans,&#8221; he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 is down 4% the past five days. High yield bonds are UP the past five days. If the end was near like they keep telling us this wouldn&#39;t be the case. Remain calm, this is simply seasonal late February shenanigans. <a href="https://t.co/FF2TtFJGz5">pic.twitter.com/FF2TtFJGz5</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1895318792634606066?ref_src=twsrc%5Etfw">February 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Furthermore, he dismissed the validity of price-to-earnings ratio, saying that there was no &#8220;correlation between P/E multiples and what stocks will do a year later.&#8221;
George Smith, portfolio strategist at LPL Financial highlighted his take on investor sentiment by analyzing survey data from the American Association of Individual Investors and Bank of America Global Fund Manager Survey.
AAII&#8217;s latest sentiment survey reveals significantly bearish sentiment among individual investors for the fourth consecutive week, with the bull-bear spread at a 10-year high. This extreme bearishness, viewed through a contrarian lens, could be a positive signal for stocks, said Smith.
However, the BofA Global Fund Manager Survey presents a more mixed picture, with professional investors cautiously optimistic about the economy but concerned about overvalued U.S. equities. Overall, these surveys suggest a relatively neutral market outlook, aligning with LPL Research&#8217;s neutral stance on equities due to a balance of positive and negative factors, explained Smith.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep on Friday:
<ul>
<li>January's personal income, spending, core and headline PCE index, advanced U.S. trade balance in goods, retail and wholesale inventories will be out by 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Richmond Fed President Tom Barkin will speak at 8:30 a.m., ET as well.</li>
</ul>
<ul>
<li>February's Chicago business barometer data will be released at 9:45 a.m., ET.</li>
</ul>
<ul>
<li>Chicago Fed President Austan Goolsbee will speak at 10:15 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) rose 0.78% in the premarket on Friday ahead of its earnings, which will be released before the opening bell. Analysts expect it to report earnings of 52 cents per share on the revenue of $2.69 billion.</li>
</ul>
<ul>
<li>Chart Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) declined 0.14% as Wall Street expects it to report quarterly earnings of $3.15 per share on revenue of $1.17 billion before the opening bell.</li>
</ul>
<ul>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) fell 1.55% ahead of its earnings, which will be released before the opening bell. Analysts expect it to report earnings of 25 cents per share on the revenue of $148.83 million.</li>
</ul>
<ul>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) was 3.41% lower despite meeting EPS and revenue estimates as it guided for lower than expected second-quarter adjusted EPS between 75 to 85 cents.</li>
</ul>
<ul>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) dropped 2.06% as it missed the revenue expectations amid a mixed quarter.</li>
</ul>
<ul>
<li>SoundHound AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) jumped 5.86% after posting a strong quarter and issuing a positive guidance for the next fiscal year.</li>
</ul>
<ul>
<li>Rocket Lab USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) slumped 10.99% as it reported a weaker than expected first quarter guidance.</li>
</ul>
<ul>
<li>Rapid Micro Biosystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) climbed 40.48% as it signed a 5-year global distribution deal with MilliporeSigma.</li>
</ul>
<ul>
<li>Virpax Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) surged 39.04% as it reported positive human study results for its Molecular Envelope Technology, a key component in its Envelta and NobrXiol products, with no moderate to severe adverse events.</li>
</ul>
<ul>
<li>Powell Max Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) zoomed 77.05% as it announced that it will acquire Miracle Media Production from Vision Access Enterprises and M Digital Partners Company. The acquisition is expected to enhance Powell Max&#8217;s services and create synergies.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 1.11% to hover around $69.57 per barrel.
The gold spot index was down by 0.53% to $2,861.73 per ounce. Its last record high was at $2,956.37. The Dollar Index was up 0.12% at the 107.373 level.
Asian markets fell on Friday, including Japan's Nikkei 225, China's CSI 300, Australia's ASX 200, India's S&amp;P BSE Sensex, South Korea's Kospi, and Hong Kong's Hang Seng index. European markets were also mostly lower in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44035798/dell-technologies-projects-15-billion-ai-server-revenue-for-fy26-raises-dividend-18-amid-a-mixed-quarter">Dell Technologies Projects $15 Billion AI Server Revenue For FY26, Raises Dividend By 18% Amid A Mixed Quarter</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Market Summary

Futures

Treasuries

Economics

NVDA

PMAX

RKLB

RPID

SOUN

VRPX

US Stocks Likely To Open Higher Following A Sell-Off, 'This Choppy Start To 2025 Isn't Abnormal. Don't Panic,' Says Expert Highlighting Seasonal Weakness In The First Quarter After Elections

<h3>Companies Reporting Before The Bell</h3>
• Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $282.62 million. 
• Nordic American Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAT#NYSE">NAT</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $53.07 million. 
• Fluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $68.06 million. 
• Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) is expected to report quarterly loss at $0.41 per share on revenue of $18.17 million. 
• Oxford Square Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXSQ#NASDAQ">OXSQ</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $9.90 million. 
• Integral Ad Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $148.94 million. 
• PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $99.26 million. 
• ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is expected to report quarterly earnings at $0.31 per share on revenue of $175.12 million. 
• TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $37.36 million. 
• Global Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLP#NYSE">GLP</a>) is estimated to report quarterly earnings at $0.90 per share on revenue of $5.80 billion. 
• Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) is expected to report quarterly loss at $0.22 per share on revenue of $7.60 million. 
• FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $444.91 million. 
• Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) is expected to report quarterly loss at $0.08 per share on revenue of $21.01 million. 
• Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRP#NYSE">NRP</a>) is projected to report earnings for its fourth quarter. 
• Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) is expected to report quarterly loss at $0.37 per share on revenue of $191.93 million. 
• Calumet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) is estimated to report quarterly loss at $0.36 per share on revenue of $929.11 million. 
• 1stdibs.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $22.02 million. 
• LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $244.81 million. 
• Fulgent Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGT#NASDAQ">FLGT</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $75.39 million. 
• Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) is estimated to report quarterly earnings at $0.53 per share on revenue of $2.73 billion. 
• Amneal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $700.83 million. 
• Banco Latinoamericano (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLX#NYSE">BLX</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $251.03 million. 
• Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) is expected to report quarterly earnings at $3.23 per share on revenue of $1.18 billion. 
• Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) is estimated to report quarterly earnings at $1.12 per share on revenue of $683.10 million. 
• Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $56.24 million. 
• Northwest Natural Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>) is expected to report quarterly earnings at $1.49 per share on revenue of $395.05 million. 
<h3>Companies Reporting After The Bell</h3>
• BIT Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) is estimated to report earnings for its fourth quarter. 
• Monroe Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCC#NASDAQ">MRCC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $14.99 million. 
• Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) is projected to report quarterly loss at $0.36 per share on revenue of $660 thousand. 
• Middlesex Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSEX#NASDAQ">MSEX</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $45.00 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMRX

ANIP

APLS

BFLY

BTCM

CLMT

DCBO

DIBS

FLGT

FLNT

FUBO

LGVN

MRCC

MSEX

OXSQ

RXRX

WULF

Earnings Scheduled For February 28, 2025

The CNN Money Fear and Greed index showed further decline in the overall market sentiment, while the index remained in the &#8220;Extreme Fear&#8221; zone on Thursday.
U.S. stocks settled lower on Thursday, with the Nasdaq Composite dipping more than 500 points during the session.
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares plunged more than 8% on Thursday after the company released fourth-quarter results.
On the economic data front, the second estimate released Thursday by the U.S. Bureau of Economic Analysis revised fourth quarter 2024 real GDP up by less than 0.1 percentage point, due mainly to higher-than-expected increases in government spending and exports.
Thursday&#8217;s data also showed initial jobless claims rose by 22,000 from the previous week to 242,000, the most in over two months and above market expectations of 221,000, indicating further softening of the job market.
Most sectors on the S&amp;P 500 closed on a negative note, with information technology, communication services and information technology stocks recording the biggest losses on Tuesday. However, financial and energy stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 194 points to 43,239.50 on Thursday. The S&amp;P 500 fell 1.59% to 5,861.57, while the Nasdaq Composite fell 2.78% at 18,544.42 during Thursday's session.
Investors are awaiting earnings results from Global Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLP#NYSE">GLP</a>), Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) and Chart Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 18.4, the index remained in the &#8220;Extreme Fear&#8221; zone on Thursday, versus a prior reading of 21.3.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/44018351/top-3-utilities-stocks-you-may-want-to-dump-in-february">Top 3 Utilities Stocks You May Want To Dump In February</a></li>
</ul>
Photo courtesy: Shutterstock

Nasdaq Tumbles Over 500 Points As Nvidia Plunges Post Q4 Results: Investor Sentiment Declines Further, Greed Index Remains In 'Extreme Fear' Zone

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Global Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLP#NYSE">GLP</a>) to report quarterly earnings at 24 cents per share on revenue of $5.80 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Global Partners shares fell 3.1% to close at $56.57 on Thursday.</li>
<li>Analysts expect Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) to post quarterly earnings at 52 cents per share on revenue of $2.69 billion. The company will release earnings before the markets open. Owens &amp; Minor shares gained 0.7% to close at $6.89 on Thursday.</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) reported first-quarter earnings of 74 cents per share, meeting the analyst consensus estimate. The company reported quarterly sales of $13.50 billion, which beat the analyst consensus estimate of $13.36 billion. The company said it sees second-quarter adjusted EPS of 75 to 85 cents versus estimates of 86 cents. HP shares fell 2.1% to close at $33.13 on Thursday.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) reported better-than-expected fourth-quarter adjusted earnings results and issued FY25 adjusted EPS guidance above estimates. Dell shares fell 6.8% to close at $107.83 on Thursday.</li>
<li>Analysts expect Chart Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) to post quarterly earnings at $3.15 per share on revenue of $1.17 billion before the opening bell. Chart Industries shares fell 2% to close at $182.25 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/02/44018351/top-3-utilities-stocks-you-may-want-to-dump-in-february">Top 3 Utilities Stocks You May Want To Dump In February</a></li>
</ul>
Photo courtesy: Shutterstock

HP, Dell Technologies And 3 Stocks To Watch Heading Into Friday

Baird analyst Eric Coldwell maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Neutral and lowers the price target from $14 to $10.

Baird Maintains Neutral on Owens & Minor, Lowers Price Target to $10

UBS analyst Kevin Caliendo maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Buy and lowers the price target from $25 to $13.

UBS Maintains Buy on Owens & Minor, Lowers Price Target to $13

Byram Healthcare, a leader in home-based care and part of the Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) family, recently launched ByramConnectTM, a personalized digital health program powered by the Welldoc App&#xAE;. Using the Welldoc App's advanced artificial intelligence capabilities, the program analyzes member data across six dimensions of health to help optimize outcomes for people with type 1 or type 2 diabetes and associated chronic conditions such as hypertension, weight management, and cardiovascular risk, providing Byram members with actionable insights and reports that can be shared with their providers and care teams.

Owens & Minor's Byram Healthcare Launches AI-Powered Digital Health Program to Support Diabetes and Chronic Conditions

Press Releases

Owens & Minor Launches Financing for Rotech Acquisition and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Results Ahead of Investor Meetings

Owens & Minor Launches ByramConnect Digital Health Platform for Diabetes and Other Chronic Health Conditions

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Owens & Minor, Inc. - OMI

Owens & Minor Reports Fourth Quarter & Full Year Financial Results and
Announces Sale Process Underway for Products & Healthcare Services Segment

Owens & Minor Announces Launch of Senior Secured Notes Offering

Owens & Minor Announces Upsize and Pricing of Senior Secured Notes Offering

Owens & Minor Announces Major Innovations to Products & Healthcare Services Network

Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

Comments

Owens & Minor

Noticias

Últimas noticias sobre Owens & Minor (NYSE:OMI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL